Overexpression of CEACAM6 increases gemcitabine chemoresistance in pancreatic adenocarcinoma cells by modulating Akt activity in a c-Src-dependent manner and inhibition of CEACAM6 restores the paclitaxel sensitivity of lung adenocarcinomas [39, 40]. Here, SRC is linked to lung adenocarcinoma.